



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

INTERNATIONAL APPLICATION PUBLIS		11) International Publication Number: WO 84/00302
(51) International Patent Classification ³ : A61L 17/00, 15/04; A61F 1/00 C08L 67/04	A1	43) International Publication Date: 2 February 1984 (02.02.84)
(21) International Application Number: PCT/N (22) International Filing Date: 15 July 1983	(15.07.	FR (European patent), GB (European patent), JP, LV (European patent), NL (European patent), NO, S (European patent), US.
(31) Priority Application Number: (32) Priority Date: 16 July 1982 (33) Priority Country:		Published With international search report.
(71) Applicant (for all designated States except of SUNIVERSITEIT TE GRONINGEN [NI erstraat 5, NL-9712 CP Groningen (NL).	US): RI _/NL]; l	K- ro- -
(72) Inventors; and (75) Inventors/Applicants (for US only): GOG- Sylvester [PL/NL]; Oostersingel 59, NL-97 ningen (NL). PENNINGS, Albert, Johan Ettenlaan 3, NL-9331 BE Norg (NL). WII Charles, Roelf, Hendrik [NL/NL]; Ossenn 9712 NZ Groningen (NL).	n [NL/I DEVU 12rkt 8,	LI; R. IL-
(74) Agent: URBANUS, H., M.; Vereenigde reaux, Nieuwe Parklaan 107, NL-2587 BF (NL).	The H	gue

(54) Title: BIOCOMPATIBLE, ANTITHROMBOGENIC, MATERIALS SUITABLE FOR RECONSTRUCTIVE SURGERY

(57) Abstract

Biocompatible, highly antithrombogenic material for reconstructive surgery, which is based on poly(L-lactic acid) and/or poly(dL-lactic acid) and segmented polyester urethanes or polyether urethanes.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

		**	Liechtenstein
	Austria	Li	
ΑT		LK	Sri Lanka
ΑU	Australia	LU	Luxembourg
BE	Belgium	MC	Monaco
BR	Brazil	MG	Madagascar
CF	Central African Republic	MR	Mauritania
CG	Congo	MW	Malawi
CH	Switzerland	NL	Netherlands
CM	Cameroon	NO	Norway
DE	Germany. Federal Republic of	RO	Romania
DK	Denmark	SE	Sweden
Ħ	Finland	SN	Senegal
FR	France	SU	Soviet Union
GA	Gabon	TD	Chad
GB	United Kingdom	TG	Togo
HU	Hungary	ĽS	United States of America
JP	Japan		
KP	Democratic People's Republic of Korea		


10

15

20

25

30



Title: Biocompatible, antithrombogenic materials suitable for reconstructive surgery.

The invention relates to a new biocompatible, highly antithrombogenic material, of adjustable porosity, compliance and biodegradability, based on polylactic acid and segmented polyurethanes, for reconstructive surgery, which can be built up in layers with different compositions and characteristics and can be modelled in various shapes by including reinforcement material. The versatility of the material according to the present invention gives it a unique adaptability to the biological tissue in which it is incorporated, so that the synthetic material is built up into a new functional entity in reconstructive surgery.

Most synthetic materials used for reconstruction do not have the same mechanical proporties as the specific biological tissue and so do not match its specific function. It is known that the specific function of tissue is the trigger of the constant rebuilding of tissue in the growth during life. The variability of the elastic properties of the material according to the present invention renders it possible to match the mechanical properties of most of the biological tissue that has to be replaced in the body.

As its porosity can be varied, the ingrowth and overgrowth of tissue for complete incorporation can be regulated to provide optimum conditions for a specific replacement. Its adjustable biodegradability makes it possible, if desired, to have the synthetic material completely replaced by biological tissue.

Because of the possibility to produce the material in layers of different compositions, it is also possible to have the characteristics of each layer match the function of the biological tissue needed to rebuild that layer.

Because the material can be modelled by the shapes of mandrels by a dipping technique, every form can be produced to match the shape of an organ to be replaced, such as a tubular neo-artery for example. But also a more complex organ such as a trachea can be produced from



15

20

25

30

35

this synthetic material, including a reinforcement material in the layers to maintain its shape during the alternating positive and negative pressures occurring in the trachea and to prevent collapsing. The constructive reinforcement material can be made of a different material, for example porous hydroxy apatite, which could induce bone formation.

Due to the biodegradability and high flexibility of the polylactide-polyurethane porous membranes, these materials can also be used to cover satisfactorily large experimental full-thickness skin wounds. Such membranes can effectively protect these wounds from infection and fluid loss for a long time.

Thus these combinations give a wide range of new possibilities in reconstructive surgery, all based on the same principle that perfect matching of the mechanical properties of biological tissue and synthetic materials creates one functional unity between biological tissue and the synthetic material which allows complete incorporation and rebuilding to a new organ. This new composition has been tested in animal experiments, primarily with rabbits, as vascular and tracheal prostheses and artificial skin. In these experiments true biocompatibility and a high degree of antithrombogenicity of the material was demonstrated. The experiments with the trachel prosthesis revealed that quick tissue ingrowth from the peritracheal tissue is induced if relatively large pores (100 μ) were used on the outside. However, overgrowth of tissue on the luminal side needed only a thin connective tissue layer to which epithelium became firmly attached and differentiated. This was achieved with relatively small pores on the inside (10 - 20 u). Between the layers of various pore sizes a reinforcement of a spiral bead may be embedded.

This possibility of variation by means of different layers can also be used for the composition of an artificial skin where such functions as controlled evaporation, ingrowth of tissue, seeding of epithelial cells and resistance to outside micro-organism require layers with different characteristics.


More specifically the invention relates to the provision of a material which comprises the following composition in wt. %:

poly(L-lactic acid) and/or poly(dL-lactic acid) with a viscosity-average



15

20



molecular weight in the range of 2 x 10⁵ to 5 x 10⁶, from 5 to 95; and polyester urethane or polyether urethane, from 5 to 95.

Polyester urethane of polyether urethane may be based on:

polytetramethylene adipate, poly(ethyleneglycol adipate), poly(tetramethylene oxide), poly(tetramethylene glycol) or poly(diethyleneglycol adipate, p,p'-diphenylmethane diisocyanate, or toluene diisocyanate, or hexamethylene diisocyanate and 1,4 butanediol or ethylene diamine.

The segmented polyurethane imparts the desired flexibility, strength and antithrombogenity to the material.

The polylactic acid ensures the required modulus and porosity. By varying the proportion of polylactic acid, the proposed compliance and type or porosity can be controlled. As the esther, ether and urethane groups of polyurethane and the carboxylic group of polylactic acid exhibit poor hydrolytic stability, the material easily breaks down to be eliminated from the body after replacement of the graft by the body tissues.

In order to increase the rate of material resorption in the body, it is recommended to use a material which contains at least 20 % by weight of polylactic acid and polyesther urethane, based on hexamethylene diisocyanate, polyethyleneglycol adipate and 1,4-butanediol.

In order to improve antithrombogenic effect, the polyurethane based on polytetramethylene glycol and p,p'-diphenylmethane may be used.

For the preparation of arteries, arteriovenous shunts or cardiopulmonary bypass, the following compositions of the material, in

- 25 % by weight, are recommended:
 - a. poly(L-lactic acid) or poly(dL-lactic acid), 20; polyether urethane, 80.
 - b. polylactic acid, 30; polyether urethane, 70.
- 30 c. polylactic acid, 15; polyether urethane, 85.

For the preparation of veins with a diameter in the range of 1,5 to 10 mm, the following composition, in % by weight, is recommended:

- a. polylactic acid, 80;
- 35 polyester urethane, 20.
 - b. polylactic acid, 70;



20

30

35

polyester urethane, 30.

c. polylactic acid, 60; polyester urethane, 40.

For the preparation of tracheal prostheses with a diameter in the range of 7 - 25 mm, the following composition, in % by weight, is recommended:

- a. polylactic acid, 50;
 polyester or polyeter urethane, 50.
- b. polylactic acid, 40;polyester of polyeter urethane, 60.

For the preparation of artificial skin having a size in the range of 50 to 500 mm by 50 to 500 mm the following composition, in the by weight; is recommended: polylactic acid, 20 to 50;

15 polyester wrethane 50 to 80.

The techniques applied for the preparation of tubular grafts and porous membranes may for example be as follows:


A. Vascular grafts

Polylactic acid is dissolved in chloroform at room temperature and 5 to 20 % by weight of sodium citrate in chloroform ethanol mixture is added to the solution. Polyurethane is dissolved in tetrahydrofuran so as to give a solution with a concentration in the range of 5 - 15 % by weight.

The solutions of polylactic acid and polyurethane are mixed together right before the preparation of the tubes.

with polytetrafluoroethylene. For this purpose the mandrels are dipped into the polymer solution and dried at room temperature. Dipping and solvent evaporation procedure is repeated to provide the graft with a required wall thickness. The grafts are extracted with distilled water and ethanol for 5 to 10 hours to remove sodium citrate.

Depending on the concentration of sodium citrate in the polymer solution and the proportion of polylactic acid, the size of the pores formed in the grafts is in the range of 5 to 200 μm . In addition the pore size may be adjusted by changing the polymer concentration in the solution from which the grafts are made. From a more concentrated solution grafts with smaller pores are obtained. When layers of polymer



are deposited on the mandrel from solutions with different polymer concentrations composite grafts are formed having a gradually increasing pore size, suitable for certain types of implants.

b) For higher concentrations of polyurethane in the mixture:
5 Polylactic acid is dissolved in tetrahydrofuran at 50 to 90°C. Polyurethane is dissolved separately in tetrahydrofuran. The two solutions are mixed together prior to the graft preparation. The concentration of polymer in the solution is in the range of 5-20 % by weight.

Tubes are prepared on stainless steel mandrels coated with polytetrafluoroethylene (PTFE), the mandrels being dipped into the polymer solution maintained at a temperature of 60 to 85°C and next into an ethanol distilled water mixture to precipitate the polymer.

Depending on the concentration of polymer in the solution, a porous structure with different pore size is formed. The structure is composed of thin, elastic polyurethane fibers covered with a thin layer of polylactic acid.

As a general rule it is recommended that more concentrated polymer solutions are used for the preparation of grafts having smaller pore sizes.

These highly porous polylactic acid - polyurethane materials composed of randomly distributed holes and elastic fibers exhibit both radial and linear compliance.

In all cases the pore-to-matrix ratio by volume can be adjusted from 0 to 90 percent.

25 B. Tracheal Prostheses

Solutions of polymers were prepared as described in Aa and Ab.

After the deposition of 2 to 3 polymer layers on the mandrel,
a reinforcing bead extruded from polyether urethane or polyamide urethane
is wound tightly around the polymer-coated mandrel and another coating
of polymer is applied. Due to partial dissolution and swelling of the
surface of the reinforcing bead, an excellent, homogenous connection
between the bead and the inner and outer walls of the prostheses is
formed.


C. Artificial skin

35

Solutions of polymers are prepared as described in Aa and Ab. A glass cylinder with a rough, sand-blasted surface is dipped into



15



the polymer solution maintained at a temperature of 60 to 85°C, and next into an ethanol distilled water mixture to precipitate the polymer.

After washing with water and extraction with ethanol the porous sleeve is removed from the glass mould and cut along its longitudinal axis.

On the upper side of the membrane a polyether urethane or Dow Corning Silastic Medical Adhesive Type A is spread.

The diameter and the length of the glass mold may be in the range of 50 to 200 mm and 50 to 200 mm, respectively, depending on the size of the piece of artificial skin required for implantation.

The proposed material in the form of vascular and tracheal grafts and porous membranes-artificio with various polylactic acid-polyurethane compositions and porosities, was tested in vivo for anticlotting properties and tissue ingrowth by implanting into chincilla rabbits and albino rats weighing 2 to 2.5 kg and 100 to 150 g, respectively.

Histological analysis showed no clotting, connective tissue ingrowth, blood vessels ingrowth, etc.



CLAIMS

- 1. Biocompatible, highly antithrombogenic material for reconstructive surgery, which is based on poly(L-lactic acid) and/or poly(dL-lactic acid) and segmented polyester urethanes or polyether urethanes.
- Material according to claim 1, characterized by the following composition in % by weight: poly(L-lactic acid), 5 to 95, or poly(dL-lactic acid), 5 to 95, and
- poly(dm=lattic acid), 5 to 95, 10 polyester urethane, 5 to 95, or

polyether urethane, 5 to 95.

- 3. Material according to claims 1-2, characterized in that the polyester urethane is based on:
- poly(tetramethylene adipate), poly(ethyleneglycol adipate), p,p'diphenylmethane diisocyanate, toluene diisocyanate, hexamethylene
 diisocyanate, and 1,4-butanediol or ethylene diamine; and the
 polyether urethane is based on:

poly(tetramethylene oxide), poly(tetramethylene glycol), poly-

- 20 (diethyleneglycol adipate), p,p'-diphenylmethane diisocyanate, toluene diisocyanate, hexamethylene diisocyanate, and 1,4-butanediol, or ethylene diamine.
 - 4. Biocompatible, highly antithrombogenic, biodegradable grafts based on polylactic acid and segmented polyurethanes, characterized in that compliance is adjusted by the ratio between the polylactic acid
- 25 that compliance is adjusted by the ratio between the polylactic acid and the polyurethane in the mixture.
 - 5. Biocompatible highly antithrombogenic, biodegradable grafts based on polylactic acid and segmented polyurethanes, characterized in that the pore size and the pore-to-matrix ratio by volume is adjusted from 0 to 90 percent.



INTERNATIONAL SEARCH REPORT

International Application No DCT/NI. 83/00027

		international Application international Application and Applic	
I. CLASSIFICA	emational Patent Classification (IPC) or to both National Patent Classification (IPC) or to both Nation	nai Classification and IPC	
According to Int	ernational Patent Classification (IPC) or to both Nation A 61 L 17/00; A 61 L 15/0	4; A 61 F 1/00; C	08 L 67/04
I. FIELDS SE	ARCHED	- Combad A	
	Minimum Document	lassification Symbols	
lassification Sys	rtem C	Marine and Cymres	
IPC ³	A 61 L 17/00; D 01	Malmum Documentation	04
	to the Extent that such Documents:	are included in the Fields Searched 6	
III DOCUMEN	ITS CONSIDERED TO BE RELEVANT 14	· · · · · · · · · · · · · · · · · · ·	Relevant to Claim No. 18
ategory *	Citation of Document, 15 with indication, where appr	oprists, of the ratevant passages	
A	FR, A, 1478694 (ETHIC see page 6, lines	ON) 28 April 1967	1
A	FR, A, 2088548 (ETHIC see page 14, line	5 1-9	1
A	FR, A, 2401185 (ETHIC		
A	FR, A, 2267748 (AMERI 14 November 1975	CAN CYANAMID)	
A	FR, A, 2440380 (F.E.		
A	FR, A, 1461386 (DU PC 1966 see abstract 2e	NT) 9 December	1
			•
"A" docum consid "E" sarlier filling c filling c thatio "O" docum other	ategories of cited documents: 18 lent defining the general state of the art which is not leved to be of particular relevance document but published on or after the international date is cited to establish the publication date of another n or other special reason (as specified) ment referring to an oral disclosure, use, exhibition or means ment published prior to the international filing date but han the priority date claimed	document is combined with or ments, such combination bein	ple or theory underlying the ince; the claimed invention or cannot be considered to ance; the claimed invention re an inventive step when the ne or more other such docu- g obvious to a person skilled
IV. CERTIF			Scoop Bodde 3
Date of the	Actual Completion of the International Search 5	Date of Mailing of this international 1 4 NOV, 198	3
1	The October 1983 Searching Authority:	Signature of Authorized Officer 10	1/1/11/11/11/19
1	ROPEAN PATENT OFFICE	G.L	M. Krydenberg

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON

INTERNATIONAL APPLICATION NO.

PCT/NL 83/00027 (SA

5479)

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 02/11/83

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
FR-A- 1478694		NL-A- BE-A- DE-A- CH-A- GB-A- SE-B-	6605197 679726 1642111 526963 1123445 353021	21/10/66 19/10/66 30/12/71 31/08/72 22/01/73
FR-A- 2088548	07/01/72	NL-A- DE-A- US-A- US-A- BE-A- CA-A- CH-A- SE-B-	7103263 2062604 3636956 3797499 758156 982007 573752 361599	16/11/71 25/11/71 25/01/72 19/03/74 28/04/71 20/01/76 31/03/76 12/11/73
FR-A- 2401185	23/03/79	DE-A- US-A- US-A- GB-A- CA-A-	2827289 4137921 4157437 1595269 1124444	11/01/79 06/02/79 05/06/79 12/08/81 25/05/82
FR-A- 2267748	14/11/75	US-A- NL-A- BE-A- DE-A- AU-A- GB-A- AT-B- JP-A- AU-B- CA-A- CH-A- SE-A- SE-B- US-A- CA-A-	3896802 7504655 828133 2515865 7899875 1476894 342214 50146181 498891 1059853 614123 7504547 411298 3903882 1066579	29/07/75 21/10/75 20/10/75 30/10/75 16/09/76 16/06/77 28/03/78 22/11/75 29/03/79 07/08/79 15/11/79 23/12/75 17/12/79 09/09/75 20/11/79
FR-A- 2440380	30/05/80	DE-A- US-A-	2827450 4156066	11/01/79 22/05/79

For more details about this annex: see Official Journal of the European Patent Office, No. 12/82

INTERNATIONAL APPLICATION NO.

PCT/NL 83/00027 (SA 5479)

For more details about this annex: see Official Journal of the European Patent Office, No. 12/82